Metabolic Profile and Anthropometric Changes in Schizophrenia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,006
- 试验地点
- 1
- 主要终点
- Study of metabolic profile
研究概览
简要总结
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
详细描述
we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18-40 years
- •Diagnosis of schizophrenia
- •Drug naive on admission
排除标准
- •Other psychiatric co-morbidity
- •History of severe physical illness
- •Alcohol and substance abuse or dependence
- •History of pre-existing diabetes or hypertension
- •Family history of hypertension or diabetes
研究组 & 干预措施
1
Olanzapine
干预措施: Olanzapine (Drug)
2
Risperidone
干预措施: Risperidone (Drug)
3
haloperidol
干预措施: Haloperidol (Drug)
结局指标
主要结局
Study of metabolic profile
时间窗: 6 weeks
次要结局
- Study of obesity and diabetes(6 weeks)
